sFcεRI als potenzieller Biomarker für Endotypes von Chronische Urtikaria (SECU)

• Antragstellerin: Sherezade Moñino-Romero, Ph.D.
• Fachliche Zuordnung: Dermatologie ; Klinische Immunologie und Allergologie
• Förderung: Förderung von 2022 bis 2024
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 504179322

• Erstellungsjahr: 2024

Zusammenfassung der Projektergebnisse

1) sFcεRI is significantly elevated in serum of CSU patients. 2) sFcεRI might be used as a biomarker for type I autoallergic CSU, which could be beneficial for treating physicians to decide on therapy and monitor during treatment. 3) Human skin MCs are able to release sFcεRI only upon IgE-mediated activation in vitro and ex vivo. 4) Human skin MCs could be the source of serum sFcεRI levels in CSU. 5) Our findings on the cellular mechanisms of sFcεRI release and the use as a biomarker could contribute in the understanding of the pathomechanisms causing symptoms in CSU patients, and to identify good candidates for omalizumab treatment.

Projektbezogene Publikationen (Auswahl)

• Elevated baseline soluble FcεRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 38(1), 167-174.
  Moñino‐Romero, S.; Kolkhir, P.; Ohanyan, T.; Szépfalusi, Z.; Weller, K.; Metz, M.; Scheffel, J.; Maurer, M. & Altrichter, S.
  
• In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria. Clinical and Translational Allergy, 13(7).
  Moñino‐Romero, Sherezade; Kolkhir, Pavel; Szépfalusi, Zsolt; Schoepke, Nicole; Metz, Martin; Asero, Riccardo; Ferrer, Marta; Gimenez‐Arnau, Ana; Grattan, Clive E. H.; Jakob, Thilo; Konstantinou, George N.; Raap, Ulrike; Staubach, Petra; Zhang, Ke; Bindslev‐Jensen, Carsten; Daschner, Alvaro; Kinaciyan, Tamar; Makris, Michael; Marrouche, Nadine ... & Altrichter, Sabine